The Food and Drug Administration (FDA) has approved Yesintek TM (ustekinumab-kfce), a biosimilar to Stelara ® (Ustekinumab), for the treatment of various chronic inflammatory diseases. Yesintek, ...

The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Applied Therapeutics regarding the New Drug Application (NDA) for govorestat for the treatment of classic ...

According to the Company, the premixed bags were developed to reduce preparation time and the risk of preparation errors.

Skysona is indicated to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy.

Aficamten is a small molecule cardiac myosin inhibitor designed to reduce the number of active actin-myosin cross bridges during each cardiac cycle.

The health system defended itself by claiming it had done nothing wrong, and that Dr T had a clear duty to inform it of the ...

More than 7 million Americans struggling with obesity would become eligible for coverage under the proposed change ...

(HealthDay News) — Antibiotic treatment for 7 days is noninferior to 14 days for hospitalized patients with bloodstream infection, according to a study published online Nov. 20 in the New England ...

Prescription rates increased from 2021 to 2023, but high variance seen between hospitals in the rate of prescriptions ...

The approval was based on data from 5 randomized, double-blind, placebo-controlled trials that included 317 patients with supraventricular tachycardia.

AXS-12 is an investigational highly selective potent norepinephrine reuptake inhibitor and cortical dopamine modulator.

Vaccination of 'mid-adults,' including those at higher risk, results in higher number needed to vaccinate than that seen for younger people ...